Laurus Labs Q2 results: net profit up 126% to Rs 441 crore; Re 1 dividend

Laurus Labs Q2 results show net profit rising 126% to Rs 441 crore for the quarter ended 30 September 2026, with revenue up 33% to Rs 2,206 crore. The company announced the numbers on 29 October 2026. The same board meeting declared an interim dividend of Re 1 per share, with a record date of 6 November 2026.

Laurus Labs Q2 results: key numbers

Measure (Rs crore unless stated)	Q2 FY27	Q2 FY26	Change
Revenue	2,206	1,653	33%
Gross margin (%)	63.0	59.9	+3.1 pts
EBITDA	762	429	78%
EBITDA margin (%)	34.5	26.0	+8.5 pts
Profit before tax (PBT)	592	270	119%
Net profit	441	195	126%
Diluted EPS (Rs)	8.2	3.6	128%

The figures are taken from the company’s press release, which does not label them as standalone or consolidated. EBITDA is earnings before interest, tax, depreciation and amortisation, a measure of operating profit. It is not the same as net profit, which is what remains after all costs and tax.

Half-year and CDMO growth

For the half year ended 30 September 2026, revenue rose 31% to Rs 4,233 crore from Rs 3,223 crore, and net profit rose 126% to Rs 809 crore from Rs 358 crore. The company said its CDMO small-molecules business reported Q2 revenue of Rs 875 crore, up 86%, and half-year revenue of Rs 1,710 crore, up 77%.

Why margins widened

The CFO said gross margin improved by more than 3 percentage points to 63% because of a favourable segment mix, and that the 34.5% EBITDA margin was supported by better capacity efficiency as commercial supplies grew. The CEO’s comment credits the CDMO platform and the Affordable Medicines portfolio for the growth. The company also said its capex reached 20% of revenue and that its first commercial-scale peptide plant at Vizag is now operating.

Dividend and record date

The board declared an interim dividend of Re 1 per share of face value Rs 2, or 50%. The company’s dividend filing sets the record date at 6 November 2026, and says the dividend will be paid on or after 19 November 2026. Shareholders on the register on the record date are eligible for the payout. Other companies with record dates in the same week are covered in the results news page, including Infosys’ record date on 3 November 2026.

What to watch next

The same release said Laurus Labs has signed definitive agreements to buy a 60% stake in Canada-based Galenvs Science, which works on oligonucleotides, and a 52% stake in SI&C Resins, a peptide-resin company. The release does not give the deal values. Watch for completion of both deals and whether Q3 revenue keeps growing at this pace.